Published in Obesity and Diabetes Week, July 20th, 2009
"The present study was designed to determine whether exposure to anti-IFRx is associated with weight loss in T2DM patients. Exposure to anti-IFRx was compared between T2DM patients with a history of weight loss (n=100) and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.